DEF: Neuronetics Schedules 2026 Annual Meeting

Neuronetics, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, detailing proposals for director elections, auditor ratification, executive compensation, and an equity incentive plan.

Summary

• Neuronetics, Inc. is holding its virtual Annual Meeting of Stockholders on May 28, 2026, at 8:00 a.m. Eastern Time.
• The meeting agenda includes the election of director nominees, ratification of KPMG LLP as the independent auditor for the fiscal year ending December 31, 2026, an advisory vote on executive compensation, and approval of the Neuronetics, Inc. 2026 Equity Incentive Plan.
• Stockholders of record as of March 30, 2026, are eligible to vote.
• The company has outlined its corporate governance practices, including board independence, leadership structure, and risk oversight.
• Detailed information on executive and director compensation for 2025 is provided, along with the proposed 2026 Equity Incentive Plan.
• The filing also includes information on security ownership by major stockholders and management, as well as related party transactions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, as it outlines standard corporate governance procedures and proposals for future incentive alignment, but also reveals ongoing net losses and mixed performance on incentive metrics.

Positives

• The company is holding its annual meeting to ensure continued corporate governance and stockholder engagement.
• The proposed 2026 Equity Incentive Plan aims to attract, retain, and motivate key personnel, aligning their interests with stockholders.
• The Board of Directors is composed of a majority of independent directors, adhering to Nasdaq listing standards.
• The company has robust committee structures (Audit, Compensation, Nominating and Corporate Governance) with independent members.
• KPMG LLP has served as the independent auditor since 2003, indicating a stable and long-standing auditor relationship.
• The company has adopted a clawback policy and stock ownership guidelines for executives and directors, promoting accountability and alignment with stockholder interests.

Negatives

• The company reported a net loss for the fiscal years 2023, 2024, and 2025, indicating ongoing financial challenges.
• The company did not satisfy the threshold performance for the EBIT metric in 2025, resulting in no payout for that component of the annual incentive plan.
• Certain performance-based equity awards granted in 2025 did not vest as expected due to financing events not contemplated at the time of grant, leading to the Compensation Committee exercising negative discretion.
• Two of the four proposals for the 2025 PRSU awards did not vest due to not meeting cash flow breakeven targets in Q3 2025.
• The company's compensation committee exercised negative discretion on a portion of 2025 PRSU awards, reducing the payout.

Risks

• The company's success depends on its ability to attract and retain top talent, which is supported by the proposed equity incentive plan.
• The company's financial performance, particularly EBIT, did not meet targets in 2025, posing a risk to future incentive payouts.
• The proposed 2026 Equity Incentive Plan, if approved, will increase the number of shares available for grant, potentially leading to further dilution for existing stockholders.
• The company's reliance on equity awards for compensation could lead to significant dilution if not managed carefully.
• The company's ability to achieve cash flow breakeven targets in future quarters is critical for the vesting of certain performance-based awards.

Future Outlook

The company is seeking stockholder approval for the Neuronetics, Inc. 2026 Equity Incentive Plan, which is intended to help attract, motivate, and retain high-quality personnel and promote the success of the company's business by providing incentives through equity ownership. The plan includes an evergreen provision for automatic annual increases in the share reserve.

Management Comments

• We believe that a stock-based compensation program is central to this objective [attracting and retaining the best available personnel].
• The Board believes that separation of the positions of Chair and Chief Executive Officer reinforces the independence of the Board in its oversight of our business and affairs.
• We encourage stockholders to log in to this website and access the webcast before the start time of the Annual Meeting.

Industry Context

StockSavvy.ai notes that Neuronetics' focus on an equity incentive plan aligns with common practices in the medical technology and healthcare sectors, where attracting and retaining specialized talent is crucial. The proposed plan's structure, including performance-based awards and an evergreen provision, reflects industry trends aimed at long-term alignment and competitive compensation.

Comparison to Industry Standards

• The proposed 2026 Equity Incentive Plan includes an 'evergreen' provision for automatic annual increases in the share reserve, a common feature in many technology and biotech companies to ensure a consistent pool of equity for compensation.
• The company's burn rate in 2025 was 4.62%, which is within a reasonable range for companies of its size and stage, though it can vary significantly based on growth initiatives and M&A activity.
• The overhang of 16.08% in 2025 indicates a moderate level of potential dilution from outstanding equity awards and available shares, which is typical for companies utilizing equity compensation.
• The compensation structure for Named Executive Officers (NEOs) includes base salary, annual cash bonuses tied to financial and individual performance, and long-term equity incentives (RSUs and PRSUs), which is a standard practice among publicly traded companies in the healthcare sector.
• The company's peer group for compensation benchmarking is not explicitly detailed, but the engagement of a compensation consultant (Alpine Rewards, LLC) is standard practice for ensuring competitive and appropriate executive and director compensation.

Management Changes

Corporate Governance

Related Party Transactions

• John W. Sullivan (son of Keith J. Sullivan) is employed in a sales function and was promoted to Vice President, Sales in February 2025. His compensation may exceed $120,000 and includes a variable commission component. This transaction was reviewed and pre-approved by the Audit Committee.
• Abigail Furlong (daughter of Stephen Furlong) was hired in February 2025 for an entry-level role as a regional account manager. Her compensation may exceed $120,000 and includes a variable commission component. This transaction was reviewed and pre-approved by the Audit Committee.
• An agreement was entered into on March 2, 2026, with entities affiliated with Madryn Asset Management, LP, where Neuronetics paid these entities a portion of an employee retention credit receivable totaling $1,122,109.45. This relates to a prior agreement between Madryn Parties and Greenbrook before Neuronetics' acquisition of Greenbrook. Madryn Asset Management, LP is the largest stockholder, and its representative, Avinash N. Amin, M.D., serves on the Board.

Stakeholder Impact

• Shareholders: The approval of the 2026 Equity Incentive Plan could lead to increased dilution. The advisory vote on executive compensation allows shareholders to express their views on compensation practices. The election of directors ensures shareholder representation on the board.
• Employees: The 2026 Equity Incentive Plan provides opportunities for equity-based compensation, potentially increasing motivation and retention.
• Management: Executive compensation is subject to advisory shareholder approval, and performance metrics influence bonus payouts and equity vesting.
• Auditors: The ratification of KPMG LLP as the independent auditor ensures continued oversight of financial reporting.

Next Steps

• Stockholders are encouraged to vote their shares by proxy or in person at the Annual Meeting.
• The company will file a Form 8-K with the SEC to announce the preliminary and final voting results of the Annual Meeting.
• If approved, the 2026 Equity Incentive Plan will become effective, and no new awards will be granted under the 2018 Plan.
• The company will continue to evaluate and implement its executive and director compensation strategies.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting and does not contain new material financial results or strategic shifts that would warrant a buy or sell recommendation. While the proposed equity plan is a positive for talent retention, the company's ongoing net losses and mixed performance on incentive metrics suggest a 'hold' position pending clearer signs of financial turnaround and sustained operational success.

Keywords

Neuronetics, Proxy Statement, Annual Meeting, Stockholders, Directors, Executive Compensation, Equity Incentive Plan, KPMG, Corporate Governance, SEC Filing